NCT02189109View on ClinicalTrials.gov

The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

April 30, 2018

Conditions
Glioblastoma Multiforme
Interventions
DRUG

NVX-108

0.2% emulsion administered i.v.

Trial Locations (4)

2010

St. Vincents Hospital Sydney, Darlinghurst

3004

Nucleus Network, Melbourne

3121

Epworth Center, Melbourne

5042

Flinders Medical Centre, Adelaide

All Listed Sponsors
collaborator

The Alfred

OTHER

lead

NuvOx LLC

INDUSTRY

NCT02189109 - The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma | Biotech Hunter | Biotech Hunter